With expertise across sectors spanning pharmaceutical, medical devices and crop sciences, Mishcon de Reya LLP provides both contentious and non-contentious assistance for clients ranging from emerging companies to multinationals. Patrick Farrant leads the life sciences group and frequently advises on mandates such as IP licences, R&D agreements and spin-outs. IP disputes specialist David Rose is geared to handle trade mark and patent cases in the UK and across Europe. Gayle Curry, who joined the team following the firm’s January 2023 merger with Taylor Vinters, is notably strong on matters connected to digital health.
Legal 500 Editorial commentary
Key clients
- AccuRx
- Binx Health Limited
- Brookfield
- Centauri Therapeutics
- DIOSynVax
- Dama Health
- Dr Reddy Laboratories
- Endomagnetics Limited
- LoQus23
- Luye Pharma
- MatchBio Limited
- Maxion
- Medoron
- Mestag Therapeutics
- Microbiotica Limited
- Nanna Therapeutics
- Nucleome Therapeutics
- Osstec Ltd
- PetMedix
- PharmEnable
- Quell Therapeutics
- RQ Bio
- RSC
- RxCelerate
- Sania Therapeutics
- Sanofi
- T-Therapeutics
- ViaNutis (previously SomaServe)
- Zentiva Pharma
Work highlights
- Advised RQ Bio on its strategic collaboration with AbCellera to identify optimal clinical candidates for up to three infectious disease targets selected by RQ Bio.
- Acting for Dr Reddy's Laboratories in a significant follow on cross-undertaking in damages claim against Warner-Lambert relating to pregabalin.
- Acted for Maxion Therapeutics Limited on an investment of £12,000,000 from various investors including LifeArc, Monograph Capital Partners I LP, and BGF Investment Management Limited.
Practice head
The lawyer(s) leading their teams.
Patrick Farrant